Grove Bank & Trust Sells 755 Shares of AstraZeneca PLC (NASDAQ:AZN)

Grove Bank & Trust cut its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 10,644 shares of the company’s stock after selling 755 shares during the period. Grove Bank & Trust’s holdings in AstraZeneca were worth $697,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of AZN. McClarren Financial Advisors Inc. raised its holdings in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in AstraZeneca in the 3rd quarter valued at $28,000. Groupama Asset Managment lifted its position in AstraZeneca by 22.9% during the 3rd quarter. Groupama Asset Managment now owns 543,398 shares of the company’s stock worth $42,000 after buying an additional 101,225 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in AstraZeneca during the 3rd quarter worth about $45,000. Finally, Versant Capital Management Inc boosted its stake in shares of AstraZeneca by 2,618.5% during the 4th quarter. Versant Capital Management Inc now owns 734 shares of the company’s stock worth $48,000 after buying an additional 707 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AZN. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Down 0.5 %

AZN stock opened at $66.60 on Monday. The business’s 50 day simple moving average is $66.11 and its 200 day simple moving average is $74.48. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The firm has a market capitalization of $206.50 billion, a PE ratio of 31.87, a PEG ratio of 1.05 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s revenue was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.87 earnings per share. As a group, research analysts anticipate that AstraZeneca PLC will post 4.11 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.